Public record
ibutamoren (MK-677): the public record
Each table is computed from the named federal dataset as of its data date; the method is under each one.
Product listings
FDA product listings naming ibutamoren (MK-677)
The FDA NDC Directory holds 5 listings naming ibutamoren (MK-677) from 4 firms: 5 bulk ingredient listings and 0 finished product listings, 0 under an FDA-approved application. A listing is a registration by a firm, not an FDA approval.
| Measure | Value | Note |
|---|---|---|
| Listings naming ibutamoren (MK-677) | 5 | |
| Bulk ingredient listings | 5 | raw material registrations, not finished medicines |
| Of those, bulk ingredient for human prescription compounding | 3 | |
| Finished product listings | 0 | |
| Listings under an FDA-approved application | 0 | |
| Firms with a listing | 4 |
How this was calculated
Searched ingredient and product names in the NDC Directory download for the exact name variants, then counted listings by FDA marketing category and by listing firm.
Current NDC Directory listings whose ingredient or product name contains ibutamoren or MK-677 or MK 677
Firms submit listings themselves. A listing does not mean FDA has reviewed the substance for safety or effectiveness, or that it may lawfully be compounded.
Clinical studies
Registered clinical studies of ibutamoren (MK-677)
ClinicalTrials.gov lists 8 registered studies that name ibutamoren (MK-677) as an intervention as of 2026-11-11. Of these, 1 are recruiting, 5 are completed and 1 are phase 3 studies.
| Measure | Value |
|---|---|
| Registered studies | 8 |
| Recruiting now | 1 |
| Not yet recruiting | 0 |
| Completed | 5 |
| Terminated, withdrawn or suspended | 2 |
| Phase 3 (including phase 2/3) | 1 |
| Phase 2 (including phase 1/2) | 6 |
| Phase 1 | 0 |
How this was calculated
Searched the ClinicalTrials.gov intervention field for the name, downloaded every matching record and counted by overall status and phase. Combined phases are counted under the higher phase. Phase not applicable covers observational, device and behavioural studies.
Studies whose intervention field matches ibutamoren or MK-677 or MK 677 or MK-0677, any condition, any country, all statuses
A registered study is not a result. Counts include studies where the drug is a comparator or background treatment, and studies that never finished or reported.
Published research
Published papers mentioning ibutamoren (MK-677)
PubMed indexes 118 papers that mention ibutamoren (MK-677) in the title or abstract, 34 of them published from 2016 to 2025. The count for 2025 is 8 and for 2024 is 1.
| Measure | Value | Note |
|---|---|---|
| Papers indexed, all years | 118 | |
| Published 2016 to 2025 | 34 | |
| Published in 2025 | 8 | |
| Published in 2024 | 1 | |
| Busiest year since 2016 | 2025 | 8 papers |
How this was calculated
Ran a PubMed title and abstract search for the exact name variants shown and recorded the count for each publication year. No filtering by study type or quality.
PubMed records with 'ibutamoren' or 'MK-677' or 'MK 677' or 'MK-0677' in the title or abstract, all article types and species
A paper that mentions a compound is not evidence that it works or is safe in people. Counts include animal, cell, review and opinion papers.
Articles on ibutamoren (MK-677)
- MK-677 (Ibutamoren) Sleep Architecture Impact: What the Clinical Evidence Actually Shows
- MK-677 (Ibutamoren) Compounding Pharmacy: 503A vs 503B, What Patients Need to Know
- MK-677 (Ibutamoren) Compounding Pharmacy FDA and State Board Enforcement History
- MK-677 (Ibutamoren) Compounding Pharmacy Quality Red Flags to Avoid
- MK-677 (Ibutamoren) + AOD-9604 Stack: Complete Protocol, Dosing, and Evidence Review
- MK-677 (Ibutamoren) + Epitalon Stack: Safety and Monitoring Guide